Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
APP Pharmaceuticals Announces Trading Information on NASDAQ of Contingent Value Rights Associated with the Acquisition by Fresenius
APP Pharmaceuticals Announces Completion of Acquisition by Fresenius - Sep 10 2008 12:44PM
APP Pharmaceuticals and Fresenius Announce Clearance of APP Acquisition by U.S. Federal Trade Commission
APP Pharmaceuticals Receives Manufacturing Approval for Three Product Codes of Heparin at Puerto Rico Facility
APP Pharmaceuticals Reports 2008 Second Quarter Net Revenues of $198 Million, Operating Income of $53 Million
APP Pharmaceuticals Announces Date for 2008 Second Quarter Financial Results and Investor Conference Call
APP Pharmaceuticals to Be Acquired by Fresenius
APP Pharmaceuticals Receives Final Approvals for Additional Dosages of Granisetron Hydrochloride Injection, USP
APP Pharmaceuticals Launches Enhanced Labeling for Heparin Sodium Injection, USP
APP Pharmaceuticals Provides Update on Issues Related to Heparin Crisis and Actions to Ensure Uninterrupted Safe Supply - May 27 2008 12:53AM
APP Pharmaceuticals Reports 2008 First Quarter Net Revenues of $148 Million, Gross Profit of $70 Million - Jun 1 2008 7:16AM
APP Pharmaceuticals Announces Date for 2008 First Quarter Financial Results and Investor Conference Call - Jun 1 2008 7:15AM
APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard J. Tajak Chief Financial Officer
APP Pharmaceuticals Receives FDA Approval for Colistimethate For Injection, USP
American Pharmaceutical Partners to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 8
Patrick Soon-Shiong, M.D., CEO of American BioScience and Larry Norton, M.D., of Memorial Sloan Kettering Receive Gilda's Club New York City Award for the Advancement of Cancer Medicine
Carlo Montagner to Be Named President of Abraxis Oncology Upon Completion of Merger of APP and ABI
American Bioscience Inc. Names Barry Flannelly, Pharm.D, MBA, as Global Vice President Sales and Marketing - Abraxis Oncology
Sir Richard Sykes, Former Glaxo Wellcome Chairman, CEO and GlaxoSmithKline Chairman, Agrees to Join the Abraxis BioScience Board of Directors
American Pharmaceutical Partners and Technoflex Announce Joint Venture to Establish Sterile Bag-Fill Capability for Injectable Drugs in the U.S.
American Pharmaceutical Partners Receives FDA Approval for Azithromycin for Injection
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
